
In today’s ACT Brief, we examine what drives inconsistent oncology trial screening, why FDA has reportedly paused its priority voucher pilot, and how patients’ use of AI is reshaping how sponsors communicate with them.
In today’s ACT Brief, we examine how cost barriers and site infrastructure limit participation in community trials, why endpoints should reflect what patients actually experience, and how the FDA expanded a prostate cancer combination to an earlier treatment setting.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.






